Loading...
Loading...
Infinity Pharmaceuticals
today announced new data from
its completed Phase 1 study of IPI-145, the company's potent, oral inhibitor
of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The data showed that
IPI-145 was well tolerated and demonstrated favorable pharmacokinetics
following administration of single and multiple doses in healthy adult
subjects. Infinity also presented data demonstrating the activity of IPI-145
in preclinical models of rheumatoid arthritis (RA). These findings were
presented at the American College of Rheumatology (ACR)/Association of
Rheumatology Health Professionals (ARHP) 2012 Annual Meeting held in
Washington, DC.
“These data show that IPI-145 is well tolerated in healthy subjects and
inhibits immune cell activation even at low doses,” stated Vito J. Palombella,
chief scientific officer at Infinity. “The profile of IPI-145 observed in this
Phase 1 trial, combined with our preclinical studies in inflammation, support
Phase 2 clinical development in patients with asthma and RA as well as other
potential inflammatory indications.”
The PI3Ks are a family of enzymes involved in multiple cellular functions,
such as cell proliferation and survival, metabolism, cell differentiation and
cellular trafficking.^1 PI3K-delta and -gamma, two isoforms of PI3K, are
necessary for adaptive and innate immunity, and the role of these enzymes in
various immune cells supports the development of IPI-145 for the treatment of
inflammatory disorders as well as hematologic malignancies.^2 Infinity
believes that IPI-145 is the only PI3K-delta and -gamma inhibitor currently in
clinical development.
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in